Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.44 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151878 | 1.00 | ALOX5AP (0.48) | ALOX5APCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL18616623 | 0.90 | CHRNB4 (0.49) | ALOX5APCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL18616624 | 0.90 | CHRNB4 (0.49) | ALOX5APCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL18295362 | 0.89 | CHRNB4 (0.45) | ALOX5APCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL18295390 | 0.89 | CHRNB4 (0.45) | ALOX5APCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL938053 | 0.86 | ABHD6 (0.50) | ALOX5APCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL27936838 | 0.86 | ABHD6 (0.50) | ALOX5APCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL938055 | 0.86 | ABHD6 (0.50) | ALOX5APCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL9241908 | 0.84 | ALOX5AP (0.51) | ALOX5APCHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL8247133 | 0.84 | ALOX5AP (0.51) | ALOX5APCHRNB4CHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
| US-20040229858-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-11-18 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | ALOX5AP 246/4885CHRNB4 1075/4885CHRNA3 1678/4885 |
| US-20040229858-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGB4 | ALOX5AP 257/4885CHRNB4 1564/4885CHRNA3 2087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.